Zomepirac: preclinical narcotic abuse liability evaluation

J. H. Woods, A. M. Young, F. Medzihradsky, C. B. Smith, M. D. Aceto, L. S. Harris, A. E. Jacobson

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

5-(4-Chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetate dihydrate (Zomepirac, Zomax®) was assessed in a variety of preparations in which narcotic agonists and antagonists have distinctive profiles. Zomepirac failed to displace tritiated etorphine significantly at concentrations up to 200 μmol/l. It was active (3-7 x 10 -5 mol/l) on both the electrically stimulated guinea pig ileum and mouse vas deferens but was less efficacious than morphine; these effects were not reversed by narcotic antagonists. Zomepirac was inactive in some analgesic assays in mice; tail-flick (1-30 mg/kg s.c.); hot plate (1-100 mg/kg s.c.); Nilsen (1-50 mg/kg s.c.); it was also inactive (1-10 mg/kg s.c.) as an antagonist of morphine in the tail-flick assay. It was, however, active in the paraphenylquinone writhing assay; this action was not reversed by naloxone (1-10 mg/kg). Zomepirac (2.5-10 mg/kg s.c.) failed to suppress signs of withdrawal produced by morphine deprivation in dependent rhesus monkeys. The intraperitoneal infusion of high doses of zomepirac (50 mg/kg 24 h or more) in rats produced toxicity. However, lower doses failed to induce narcotic-like dependence over a 6-7-day infusion period. The compound failed to maintain intravenous drug self-administration responding in rhesus monkeys over a range of doses (0.1-3.2 mg/kg) although codeine did so. In rhesus monkeys trained to discriminate narcotic agonists (etorphine or ethylketazocine) from saline, zomepirac (1-10 mg/kg i.m.) failed to produce drug-appropriate responding. Thus, zomepirac appears to possess few, if any, of the characteristic actions of narcotics that are associated with their abuse liability.

Original languageEnglish (US)
Pages (from-to)218-222
Number of pages5
JournalArzneimittel-Forschung/Drug Research
Volume33
Issue number2
StatePublished - 1983
Externally publishedYes

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint

Dive into the research topics of 'Zomepirac: preclinical narcotic abuse liability evaluation'. Together they form a unique fingerprint.

Cite this